KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $1.1 million.

  • Halozyme Therapeutics' Change in Inventory rose 15560.61% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 5883.37%. This contributed to the annual value of $67.4 million for FY2024, which is 15063.61% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Change in Inventory of $1.1 million as of Q3 2025, which was up 15560.61% from $14.5 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Change in Inventory peaked at $40.2 million during Q1 2024, and registered a low of -$6.3 million during Q1 2022.
  • For the 5-year period, Halozyme Therapeutics' Change in Inventory averaged around $6.3 million, with its median value being $1.1 million (2025).
  • As far as peak fluctuations go, Halozyme Therapeutics' Change in Inventory tumbled by 17275.41% in 2021, and later soared by 1771744.19% in 2022.
  • Halozyme Therapeutics' Change in Inventory (Quarter) stood at -$2.2 million in 2021, then soared by 232.72% to $2.9 million in 2022, then tumbled by 149.88% to -$1.5 million in 2023, then soared by 625.94% to $7.7 million in 2024, then crashed by 85.75% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $14.5 million for Q2 2025, and $586000.0 during Q1 2025.